One of the most challenging brain tumours to treat is called ependymoma. A unique partnership called BIOMECA is made up of leading European specialists who are currently collecting samples from children with the disease. Their ultimate aim is to develop new risk categories and work towards the personalisation of treatments and therapies.
Our funding is giving a European partnership of brain tumour specialists the opportunity to better understand the biological activity of tumours in young people, and improve the effectiveness and accuracy of treatments.
BIOMarkers of Ependymomas in Children and Adolescents (BIOMECA) - Integrated Biological study within SIOP Ependymoma II trial organised by European Ependymoma Biology
Professor Richard Grundy
Children’s Brain Tumour Research Centre, University of Nottingham
Nottingham, NG7 2UH
1 December 2015